Adam V. Patterson

University of Auckland — New Zealand

Biochemistry, Genetics and Molecular Biology · Life Sciences

45h-index6.7kcitations262works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer, Hypoxia, and Metabolism(114), Cancer Research and Treatments(52), Epigenetics and DNA Methylation(32), Virus-based gene therapy research(27), Lung Cancer Treatments and Mutations(25)

Publications261 total

Structure-Based Design of 4-(1-Methyl-1 <i>H</i> -indol-3-yl)pyrimidin-2-amine Derivatives as the First Covalent FGFR3 Selective Inhibitors
Journal of Medicinal Chemistry·2026· 1 cited
Design, Synthesis, and Biological Evaluation of the First Novel Macrocycle-Based FGFR Inhibitors That Overcome Clinically Acquired Resistance
Journal of Medicinal Chemistry·2026
Design, Synthesis and Biological Evaluation of 7-(1-Methyl-1<i>H</i>-indole-3-yl)-5<i>H</i>-pyrrolo[2,3-<i>b</i>]pyrazine Derivatives as Novel Covalent pan-FGFR Inhibitors to Overcome Clinical Resistance
Journal of Medicinal Chemistry·2025· 3 cited
Inhibition of MBTPS1 enhances antitumor immunity and potentiates anti-PD-1 immunotherapy
Nature Communications·2025Open Access
Optimization of Aminoindazole derivatives as highly selective covalent inhibitors for wild-type and mutant FGFR4
Bioorganic Chemistry·2025· 2 cited
Deciphering the role of lncRNA-mediated ceRNA network in disuse osteoporosis: insights from bone marrow mesenchymal stem cells under simulated microgravity
Frontiers in Medicine·2025· 1 citedOpen Access
Tarloxotinib targets tumor hypoxia to improve therapeutic efficacy of immune checkpoint inhibition in a TLR9 dependent manner
2025Open Access
Introduction: Presenting Conceptual and Practical Approaches to Emerging Market Valuation
Contributions to finance and accounting·2025
The Emerging Markets Investment Landscape: Past, Present, and Future
Contributions to finance and accounting·2025
Optimization of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors for Wild-Type and Mutant Fgfr4
SSRN Electronic Journal·2025Open Access
超短环肽Cy&lt;sub&gt;RL-QN15&lt;/sub&gt;作为TLR4拮抗剂加速口腔溃疡愈合
动物学研究·2025· 15 citedOpen Access
The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia
Blood Cancer Journal·2024· 5 citedOpen Access
705 Hypoxia-activated prodrugs with distinct mechanisms of action sensitize murine prostate tumors to immune checkpoint blockade
Regular and Young Investigator Award Abstracts·2024Open Access
129 (PB117): Harnessing hypoxia: CP-506’s journey from bench to bedside in cancer therapy
European Journal of Cancer·2024
Structural Evaluation of a Nitroreductase Engineered for Improved Activation of the 5-Nitroimidazole PET Probe SN33623
International Journal of Molecular Sciences·2024Open Access
Discovery of 6-Formylpyridyl Urea Derivatives as Potent Reversible-Covalent Fibroblast Growth Factor Receptor 4 Inhibitors with Improved Anti-Hepatocellular Carcinoma Activity
Journal of Medicinal Chemistry·2024· 5 citedOpen Access
Tumor-targeting bacteria as immune stimulants – the future of cancer immunotherapy?
Critical Reviews in Microbiology·2024· 8 citedOpen Access
Clostridium Bacteria: Harnessing Tumour Necrosis for Targeted Gene Delivery
Molecular Diagnosis & Therapy·2024· 13 citedOpen Access
The AKR1C3-Activated Prodrug, Achm-025, Eradicates Disease in Preclinical Models of Aggressive T-Cell Acute Lymphoblastic Leukemia
Blood·2023Open Access
Design and Biological Evaluation of Piperazine-Bearing Nitrobenzamide Hypoxia/GDEPT Prodrugs: The Discovery of CP-506
ACS Medicinal Chemistry Letters·2023· 7 citedOpen Access
page 1 of 14Next →

Frequent Co-authors

Jeff B. Smaill(16), William R. Wilson(15), Christopher P. Guise(11), Ian J. Stratford(8), William A. Denny(8), Alexandra M. Mowday(8), David F. Ackerley(7), Gabi U. Dachs(5), Adrian L. Harris(5), Janine N. Copp(5), Susan M. Pullen(4), Sophie P. Syddall(4), Robert F. Anderson(4), Ke Ding(4), Michael P. Hay(4), Jeremy Brown(4), Dianne M. Ferry(3), Rachelle S. Singleton(3), Kevin O. Hicks(3), Amir Ashoorzadeh(3)